Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 19Carcinoma, Hepatocellular 18Pancreatic Neoplasms 14Colorectal Neoplasms 12Esophageal Neoplasms 9Neoplasm Metastasis 8Esophageal Squamous Cell Carcinoma 7Biliary Tract Neoplasms 7Lung Neoplasms 6Liver Neoplasms 6Cholangiocarcinoma 6Breast Neoplasms 6Neoplasms 5Colonic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Melanoma 3Sarcoma 2Rectal Neoplasms 2Advanced Pancreatic Cancer 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Resectable Esophageal Squamous Cell Carcinoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Cancer Metastatic 1Ovarian Neoplasms 1Oligometastatic Gastrointestinal Cancer 1

Interventions

PM 01183 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Malignancies × Injections × Gastrointestinal × Clear all
NCT05229588 2025-08-15

Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations

HonorHealth Research Institute

Phase 2 Completed
8 enrolled
Gastrointestinal

Gastrointestinal Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡